MedTrace Logo

Staccato Alprazolam Single Dose PK

NCT00444522 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-03-14

No results posted yet for this study

Summary

We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.

Conditions

  • Healthy

Interventions

DRUG

Alprazolam thermal aerosol

Sponsors & Collaborators

  • Alexza Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Randall Stoltz, MD · West Pharmaceutical Services, GFI Research Center, Evansville, IN 47714

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2005-08-31
Completion
2005-08-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00444522 on ClinicalTrials.gov